|1.||Yang, Xi-Ming: 4 articles (10/2013 - 05/2006)|
|2.||Downey, James M: 4 articles (10/2013 - 05/2006)|
|3.||Cohen, Michael V: 4 articles (10/2013 - 05/2006)|
|4.||Acharya, Arbind: 3 articles (06/2015 - 10/2013)|
|5.||Kumar, Sanjay: 3 articles (06/2015 - 10/2013)|
|6.||Cui, Lin: 3 articles (10/2013 - 05/2006)|
|7.||Ulrichová, J: 3 articles (11/2006 - 01/2003)|
|8.||Yao, Huan: 2 articles (12/2014 - 02/2014)|
|9.||Li, Weifeng: 2 articles (12/2014 - 12/2012)|
|10.||Niu, Xiaofeng: 2 articles (12/2014 - 12/2012)|
02/01/2007 - "When administered before sustained ischemia, chelerythrine (a PKC inhibitor) abolished both the IH-induced reduction in infarct size (36.1+/-4.9%) and improvement in hemodynamic parameters. "
05/01/2012 - "IPC was induced by 10 min of ischemia following 10 min of reperfusion prior to sustained ischemia, and chelerythrine, a PKC inhibitor, was injected 10 min before IPC (5 mg/kg, i.v.). "
09/01/2007 - "IPC limited infarct size in isolated rabbit hearts subjected to 30-min regional ischemia/2-h reperfusion and IPC's protection was blocked by the PKC inhibitor chelerythrine given during early reperfusion revealing involvement of PKC at reperfusion. "
05/04/2007 - "Treatment of IHA and normoxia cardiomyocytes with 5 microM chelerythrine delayed the pH(i) recovery during post-ischemia. "
09/01/1999 - "Isolated rat hearts were subjected to 30 min of global ischemia with and without the specific PKC inhibitor chelerythrine. "
05/01/2006 - "Intraplantar chelerythrine (2, 6 or 10 microg), a PKC inhibitor, dose-dependently attenuated the hyperalgesia evoked by alpha-m-5-HT. "
02/14/2003 - "Intrathecal injection of the PKC inhibitor, chelerythrine (10 microg), significantly inhibited the thermal hyperalgesia observed in PTX-treated rats. "
03/01/2008 - "In contrast, pre-treatment with chelerythrine chloride dose-dependently inhibited BV-induced sustained nociception and inflammation, but not the mechanical hyperalgesia. "
10/01/2005 - "In marked contrast, pretreatment with either a PKA (10nmol H89) or PKC (30nmol chelerythrine) inhibitor blocked allodynia. "
01/01/2002 - "3. Intraplantar co-injection of chelerythrine (10 or 50 microg), a PKC inhibitor, attenuated the thermal hyperalgesia induced by PDD (0.1 microg) in rats. "
10/01/2012 - "This allowed the observation of a chelerythrine-induced concentration-dependent apoptosis to necrosis switch and time-dependent progression of early apoptotic cells towards a necrotic-like phenotype. "
01/01/2005 - "The PKC inhibitors, H7 (100 microM) and chelerythrine (2.5 microM), both prevented significantly TCDC-induced necrosis. "
06/01/2008 - "We conclude that both chelerythrine and dihydrochelerythrine affect cell cycle distribution, activate mitochondrial apoptotic pathway, and induce apoptosis and necrosis in HL-60 cells."
06/01/2003 - "Protection against necrosis was eliminated by 5-HD but unaltered by chelerythrine or L-NAME during the 'mediation' phase (ischemia-reperfusion). "
07/01/2006 - "When inhibitors of mitoKATP channels (1 mm 5-hydroxydecanoate), PKC (10 microm chelerythrine), and p38MAPK (10 microm SB203580) were added for 10 min before SI, the protection against necrosis was abolished. "
01/01/2013 - "Overexpression of GAPDH significantly augmented the Mst1 mediated apoptosis, whereas knockdown of GAPDH markedly attenuated the Mst1 activation and cardiomyocyte apoptosis in response to either chelerythrine or hypoxia/reoxygenation. "
05/01/2010 - "Cultured myocardial cells were divided into the control group, the hypoxia/reoxygenation group, the EPO group and the chelerythrine group, and a hypoxia/reoxygenation model of cardiocytes was reproduced. "
12/01/2004 - "To study this, isometric force displacement was measured in isolated rat pulmonary artery rings during hypoxia in the presence and absence of the PKC inhibitors calphostin C or chelerythrine. "
11/01/2005 - "Moreover, inhibition of PKC with chelerythrine chloride (10 microM) attenuated the hypoxia-induced increases in [14C]sucrose permeability. "
05/01/2003 - "A specific inhibitor of protein kinase C (PKC), chelerythrine (3 microM), significantly attenuated the protective effect of KR466 against hypoxia-induced cardiac cell death. "
|5.||Bipolar Disorder (Mania)
08/01/2014 - "To further evaluate this possibility, the aim of the present study was to test the effects of peripheral (intraperitoneal) administration of chelerythrine in a battery of mania-related behavioral tests in black Swiss mice, a strain specific battery that was previously demonstrated to distinguish differential effects of mood stabilizing drugs. "
08/01/2014 - "Sub-chronic administration of 1.0mg/kg or 2.0mg/kg chelerythrine had marginal effects to reduce spontaneous activity and sweet solution preference in black Swiss mice which naturally show mania-like behaviors. "
06/03/2013 - "Our results showed that a single injection of the PKC inhibitors tamoxifen (80 mg/kg, i.p.) and chelerythrine (3 mg/kg, s.c.) attenuated amphetamine-induced hyperlocomotion and decreased risk-taking behavior, supporting the efficacy of PKC blockade in acute mania. "
12/12/2008 - "In the present study, the effects of tamoxifen, chelerythrine (a PKC inhibitor) and medroxyprogesterone (an antiestrogenic drug) were investigated in amphetamine-induced hyperlocomotion of mice, an animal model of a manic state. "
|1.||Protein Kinase C
|2.||mitochondrial K(ATP) channel
|6.||NG-Nitroarginine Methyl Ester (L-NAME)
|7.||N- (2- (4- bromocinnamylamino)ethyl)- 5- isoquinolinesulfonamide (h89)
|8.||Protein Kinases (Protein Kinase)
|10.||1- (5- Isoquinolinesulfonyl)- 2- Methylpiperazine (H 7)
|2.||Heterologous Transplantation (Xenotransplantation)